Onco-Innovations Announces Closing of Private Placement

Executive Summary

• Onco‑Innovations Limited closed a non‑brokered private placement of 1,428,570 units at $1.40 per unit, generating $2 million in gross proceeds.
• Each unit includes one common share and half of a warrant to purchase an additional share at $2.00 for up to 36 months.
• Proceeds are earmarked for general corporate, working‑capital, R&D, operational and investor‑relations purposes.

Key Details

• Units sold: 1,428,570 (each = 1 common share + ½ warrant)
• Price per unit: $1.40
• Aggregate gross proceeds: $2,000,000
• Warrant terms: Right to purchase one common share at $2.00 exercisable for 36 months from issuance.
• Finder compensation: $119,999.94 paid and 85,714 warrants issued to finders for introducing subscribers.
• Administrative shares: 14,286 common shares issued to an arm’s‑length third party as consideration for administrative services related to the placement.
• Use of proceeds: General corporate and working capital, including support for operational activities, research & development, and investor‑relations initiatives.
• Statutory hold period: All securities subject to a four‑month‑plus‑one‑day hold period under applicable securities laws.
• U.S. securities disclaimer: Securities not registered in the United States; cannot be offered or sold there absent exemption or registration.

Notable Quotes

• “The successful closing of this private placement provides us with essential capital to advance our oncology research and strengthen our operational capabilities.” – Thomas O’Shaughnessy, CEO

All boilerplate, forward‑looking statements and company background have been omitted for brevity.